Skip to main content
    E

    Esperion Therapeutics Inc (ESPR)

    Official site

    DRUG MANUFACTURERS - SPECIALTY & GENERIC

    $3.18
    +0.00 (+0.00%)

    Last updated: Jul 13, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(20/38)
    Avg Surprise
    +100.14%

    Upcoming Estimates

    Period ending Jun 30, 2026
    EPS Consensus$-0.07
    Range$-0.07 - $-0.07
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.01-944.8%
    60d ago$-0.070.0%
    30d ago$-0.070.0%
    7d ago$-0.070.0%
    Current$-0.07
    Revenue Consensus
    $77M
    Range$77M - $77M
    1 analysts
    Period ending Sep 30, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.04
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.01-697.0%
    60d ago$-0.040.0%
    30d ago$-0.040.0%
    7d ago$-0.040.0%
    Current$-0.04
    Revenue Consensus
    $86M
    Range$86M - $86M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.07---
    Sep 26EST
    		-$-0.04---
    Jun 26EST
    		-$-0.07---
    Mar 26
    Reported May 8
    		$-0.10$-0.04-150.00%Miss+52.4%
    Dec 25
    Reported Mar 10
    		$0.22$0.28-21.43%Miss+317.2%
    Sep 25
    Reported Nov 6
    		$-0.16$-0.08-100.00%Miss-6.7%
    Jun 25
    Reported Aug 5
    		$-0.02N/A+87.50%Beat+60.0%
    Mar 25
    Reported May 6
    		$-0.21$-0.15-40.00%Miss-161.8%
    Dec 24
    Reported Mar 4
    		$-0.10$-0.16+35.68%Beat+79.7%
    Sep 24
    Reported Nov 7
    		$-0.15$-0.17+11.76%Beat+59.5%
    Jun 24
    Reported Aug 12
    		$-0.05N/A+70.59%Beat+89.1%
    Mar 24
    Reported May 7
    		$0.34$-0.01+3500.00%Beat+143.0%
    Dec 23
    Reported Feb 27
    		$-0.50$-0.48-4.17%Miss+34.2%
    Sep 23
    Reported Nov 7
    		$-0.37$-0.42+11.90%Beat+54.3%
    Jun 23
    Reported Aug 1
    		$-0.46$-0.63+26.98%Beat+56.2%
    Mar 23
    Reported May 9
    		$-0.79$-0.66-19.70%Miss+15.1%
    Dec 22
    Reported Feb 21
    		$-0.76$-0.85+10.59%Beat+57.1%
    Sep 22
    Reported Nov 1
    		$-0.81$-0.93+12.90%Beat+69.1%
    Jun 22
    Reported Aug 2
    		$-1.05$-0.92-14.13%Miss+37.1%
    Mar 22
    Reported May 3
    		$-0.93$-1.04+10.58%Beat+73.4%
    Dec 21
    Reported Feb 22
    		$-1.77$-2.27+22.03%Beat+54.5%
    Sep 21
    Reported Nov 2
    		$-2.62$-2.80+6.43%Beat+14.7%
    Jun 21
    Reported Aug 3
    		$-1.67$-1.85+9.73%Beat-138.7%
    Mar 21
    Reported May 4
    		$-3.50$-2.72-28.68%Miss-23.2%
    Dec 20
    Reported Feb 23
    		$-3.89$-3.76-3.46%Miss-72.1%
    Sep 20
    Reported Nov 2
    		$-3.07$-3.57+14.01%Beat-21.8%
    Jun 20
    Reported Aug 10
    		$4.32$1.40+208.57%Beat+314.9%
    Mar 20
    Reported May 6
    		$-2.84$-3.30+13.94%Beat-192.5%
    Dec 19
    Reported Feb 27
    		$-2.26$-2.67+15.36%Beat-0.9%
    Sep 19
    Reported Nov 6
    		$-2.52$-1.92-31.25%Miss-35.5%
    Jun 19
    Reported Aug 8
    		$-2.01$-1.82-10.44%Miss-17.5%
    Mar 19
    Reported May 8
    		$3.07$0.74+314.86%Beat+277.5%
    Dec 18
    Reported Feb 28
    		$-2.24$-1.12-100.00%Miss-55.6%
    Sep 18
    Reported Nov 1
    		$-1.86$-1.64-13.41%Miss+0.0%
    Jun 18
    Reported Aug 2
    		$-1.71$-1.72+0.58%Beat+10.9%
    Mar 18
    Reported May 2
    		$-1.73$-1.59-8.80%Miss+3.9%
    Dec 17
    Reported Feb 20
    		$-1.44$-1.79+19.55%Beat-11.6%
    Sep 17
    Reported Nov 7
    		$-1.86$-1.77-5.08%Miss-
    Jun 17
    Reported Aug 8
    		$-1.92$-1.62-18.52%Miss-
    Mar 17
    Reported May 4
    		$-1.80$-1.46-23.29%Miss-
    Dec 16
    Reported Feb 22
    		$-1.29$-1.22-5.74%Miss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.17
    SMA 20$3.16
    SMA 50$3.12
    SMA 200$3.06
    EMA 10$3.17
    EMA 20$3.16
    EMA 50$3.06
    EMA 200$2.80

    MACD

    Line: 0.03Signal: 0.04Hist: -0.01

    ADX

    ADX: 35.8+DI: 24.1-DI: 11.4

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down52.0
    PSAR$3.11

    Bollinger Bands

    Upper Band$3.19
    Lower Band$3.14
    %B Position169%(Upper)
    Band Width0.83

    RSI (14-Day)

    Neutral
    64.8

    Momentum Oscillators

    Stoch %K88.9
    Stoch %D91.7
    Williams %R-16.7
    ROC (10d)0.3%
    Momentum0.01
    CCI (20d)147.4
    MFI (14d)88.1

    Volatility Measures

    ATR (14d)$0.02(0.7%)
    StdDev (20d)0.01
    Hist Vol6.2%(Low)

    Volume Flow

    VWAP$3.18
    OBV329.2M
    AD Line-43.7M
    CMF (20d)0.110

    Volume Metrics

    Avg Vol (20d)15.7M
    Vol RatioN/A
    VWMA (20d)$3.17

    Pivot Points

    R3$3.20
    R2$3.19
    R1$3.19
    Pivot Point$3.18
    S1$3.18
    S2$3.17
    S3$3.17

    Advanced Oscillators

    TSI32.74
    Ultimate Osc53.4
    KST9.03

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$80.10M$168.45M$87.31M$82.39M$65.00M$69.11M$51.63M$73.83M$137.74M$32.25M$33.97M$25.79M
    Cost of Revenue$0$129.22M$0$0$0$68.60M$0$0$0$43.27M$0$0
    Gross Profit$80.10M$39.22M$87.31M$82.39M$65.00M$512,000$51.63M$73.83M$137.74M$-11,017,000$33.97M$25.79M
    Operating Expenses$86.69M$-46,011,000$97.27M$75.29M$87.09M$4.93M$67.66M$71.25M$65.47M$31.35M$61.50M$62.84M
    R&D$8.99M$13.93M$14.13M$7.24M$12.56M$10.98M$10.40M$11.46M$13.40M$17.74M$14.88M$22.10M
    SG&A$77.70M$-59,937,000$83.14M$68.05M$74.53M$-6,045,000$57.26M$59.79M$52.06M$13.61M$46.62M$40.74M
    Operating Income$-6,581,000$85.23M$-9,959,000$7.09M$-22,096,000$-4,420,000$-16,026,000$2.58M$72.27M$-42,367,000$-27,533,000$-37,058,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$19.80M$22.64M$22.05M$20.49M$19.43M$18.11M$15.08M$66.96M$14.02M$15.06M$14.99M$14.54M
    Income Before Tax$-26,379,000$66.09M$-32,010,000$-13,391,000$-41,527,000$-16,087,000$-29,524,000$-64,379,000$58.24M$-53,406,000$-42,528,000$-51,595,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-25,196,000$61.83M$-31,333,000$-12,725,000$-40,455,000$-21,318,000$-29,524,000$-61,925,000$61.02M$-56,344,000$-41,250,000$-49,935,000
    EBITDA$-5,965,000$85.90M$-9,086,000$7.94M$-21,371,000$-4,221,000$-13,969,000$3.03M$72.71M$-41,930,000$-27,080,000$-36,658,000
    EBIT$-6,581,000$85.23M$-9,959,000$7.09M$-22,096,000$-4,420,000$-14,442,000$2.58M$72.27M$-42,367,000$-27,533,000$-37,058,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ESPR

    News

    Esperion Therapeutics, Inc. Revenue Breakdown – LS:A1W1SJ

    Esperion Therapeutics, Inc. (A1W1SJ) reported total revenue of €343.24 million last year, primarily from its "Patients with Elevated Low-density Lipoprotein Cholesterol" segment. The United States was the company's...

    TradingView•8/1/26•Neutral

    Vanguard Capital Management (ESPR) reports 13.1M-share, 5.08% stake in Esperion

    Vanguard Capital Management has reported a 5.08% stake in Esperion Therapeutics Inc. (ESPR), amounting to 13,105,104 shares. The filing indicates Vanguard has sole voting power over 1,677,667 shares and sole dispositive...

    Stock Titan•7/31/26•Neutral

    Esperion Therapeutics Inc (ESPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

    This article from TradingKey provides a revenue breakdown for Esperion Therapeutics Inc (ESPR). It states that relevant data regarding business segments, regional revenue...

    TradingKey•7/28/26•Neutral

    Esperion Therapeutics Inc (ESPR) Dividends & Stock Splits: Historical Payouts and Event Timeline

    The article provides an overview of Esperion Therapeutics Inc (ESPR) focusing on its dividends and stock splits. It states that no dividends have been distributed over the past five years. The current stock price is...

    TradingKey•7/27/26•Neutral

    Esperion Therapeutics Inc (ESPR) Cash Flow

    This article provides a detailed cash flow statement for Esperion Therapeutics Inc (ESPR), showing quarterly and annual data for operating, investing...

    TradingKey•7/26/26•Neutral

    ESPR Competitors

    CompanyTicker
    Ardelyx IncARDX
    Ginkgo Bioworks HoldingsDNA
    P3 Health Partners IncPIII
    Corvus Pharmaceuticals IncCRVS
    InMode LtdINMD
    Varex Imaging CorpVREX
    Monte Rosa Therapeutics IncGLUE
    Geron CorporationGERN

    Sector: Healthcare

    ESPR Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -13.2%
    EPS estimate (fiscal period ending Jun 30, 2026)
    $-0.07
    Estimate revisions (30 days, fiscal period ending Jun 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About ESPR

    Does ESPR pay dividends?

    Esperion Therapeutics Inc (ESPR) does not currently pay a regular dividend.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In